| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2006.10.0784 |
| P698 | PubMed publication ID | 17606971 |
| P50 | author | Sandra M. Swain | Q37839297 |
| P2093 | author name string | Jennifer A Low | |
| James J Lee | |||
| Seth M Steinberg | |||
| Sherry X Yang | |||
| Catherine K Chow | |||
| Janice M Walshe | |||
| Neelima Denduluri | |||
| Arlene W Berman | |||
| Ujala Vatas | |||
| P2860 | cites work | Genomic signatures to guide the use of chemotherapeutics. | Q34576027 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ixabepilone | Q11711607 |
| metastatic breast cancer | Q12859063 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 3421-3427 | |
| P577 | publication date | 2007-07-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes | |
| P478 | volume | 25 |
| Q58599310 | A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model |
| Q43152531 | A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma |
| Q33387547 | A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial |
| Q24615262 | Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer |
| Q35975007 | Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone |
| Q33999018 | Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. |
| Q26865369 | Beyond taxanes: the next generation of microtubule-targeting agents |
| Q83329362 | Clinical studies with epothilones |
| Q36245461 | Current approaches to the management of Her2-negative metastatic breast cancer |
| Q26865654 | Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets |
| Q47388453 | Epothilone B impairs functional recovery after spinal cord injury by increasing secretion of macrophage colony-stimulating factor |
| Q64991024 | Integration of Genomic Data with NMR Analysis Enables Assignment of the Full Stereostructure of Neaumycin B, a Potent Inhibitor of Glioblastoma from a Marine-Derived Micromonospora. |
| Q34611801 | Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. |
| Q28534786 | Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial |
| Q37356274 | Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer |
| Q34788890 | Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer |
| Q34417996 | Ixabepilone development across the breast cancer continuum: a paradigm shift |
| Q46173239 | Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium |
| Q34180965 | Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials |
| Q34562783 | Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients |
| Q37290709 | Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer |
| Q28298312 | Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer |
| Q37563451 | Ixabepilone: in locally advanced or metastatic breast cancer |
| Q36714374 | Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation |
| Q37403186 | Management of advanced breast cancer with the epothilone B analog, ixabepilone |
| Q53271035 | Mitosis is not a key target of microtubule agents in patient tumors. |
| Q37057994 | New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. |
| Q34611212 | Novel microtubule-targeting agents - the epothilones. |
| Q37321909 | Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone |
| Q34636002 | Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm |
| Q34204598 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer |
| Q33384027 | Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consort |
| Q37104791 | Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors |
| Q61624734 | Phase I trial of dasatinib and ixabepilone in patients with solid tumors |
| Q36988082 | Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors |
| Q34307937 | Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary |
| Q30433670 | Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study |
| Q34915389 | Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group |
| Q34274925 | Present and future evolution of advanced breast cancer therapy |
| Q35847455 | Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC |
| Q37950515 | Recent developments in treatment stratification for metastatic breast cancer |
| Q35076330 | Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence |
| Q34587678 | The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies |
| Q37791482 | The microtubule as a breast cancer target |
| Q37207961 | Treatment options for breast cancer resistant to anthracycline and taxane |
| Q42621663 | Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study |
| Q37350227 | Update on medication-induced peripheral neuropathy |
Search more.